A novel triple-knockout allogeneic BCMA CAR T-cell therapy (CT0590) for multiple myeloma: preclinical and phase 1 study.

In 30 seconds

This phase 1 clinical trial evaluated a novel allogeneic BCMA CAR T-cell therapy (CT0590) in 5 patients with relapsed and refractory multiple myeloma or primary plasma cell leukemia. The therapy was well tolerated, with no dose-limiting toxicities, and resulted in confirmed responses in 3 patients, including 2 achieving stringent complete response lasting over 20 months.

Key findings

• Three patients achieved confirmed responses, including 2 with stringent complete response.
• The duration of response was over 23 months for one patient with RRMM.
• Maximum concentration of CAR T cells was >280,000 copies per µg genomic DNA.
• Higher baseline NKG2A expression on NK cells was observed in responders compared to nonresponders.

Why it matters

The study highlights a promising approach to enhance the efficacy of allogeneic CAR T-cell therapy by mitigating host-versus-graft reactions, which could improve outcomes for patients with difficult-to-treat hematologic malignancies.